IL17A and neoplasm: This can be attributed to the low expression of CTLA-4 by IL-17-producing Tregs, which leads to Forkhead box O 3 (FoxO3) inactivation in DCs and the activation of the IL-6 production-STAT3 signaling pathway in tumor cells, ultimately promoting their proliferation.